Francisco J. Esteva: Can PROTACs Beat ESR1 Mutations in Breast Cancer?
Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital and a Professor of Medicine at the Zucker School of Medicine, shared a post on LinkedIn:
“Can PROTACs Beat ESR1 Mutations in Breast Cancer?
PROTACs (proteolysis-targeting chimeras) are designed to degrade the estrogen receptor itself. The VERITAC-2 trial showed promising results for ARV471 (vepdegestrant) in patients who previously progressed on endocrine therapy and have ESR1 mutations.
If approved by the FDA, this could mark a major shift in how we treat endocrine-resistant disease—offering patients a targeted, oral alternative that removes the receptor entirely rather than blocking it.
To learn more see video.”
Title: Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Authors: Mario Campone, Michelino De Laurentiis, Komal Jhaveri, Xichun Hu, Sylvain Ladoire, Anne Patsouris, Claudio Zamagni, Jiuwei Cui, Marina Cazzaniga, Timucin Cil, Katarzyna J. Jerzak, Christian Fuentes, Tetsuhiro Yoshinami, Alvaro Rodriguez-Lescure, Ahmet Sezer, Andrea Fontana, Valentina Guarneri, Andrea Molckovsky, Marie-Ange Mouret-Reynier, Umut Demirci, Yongqiang Zhang, Olga Valota, Dongrui R Lu, Marcella Martignoni, Janaki Parameswaran, Xin Zhi, Erika P. Hamilton
Read the Full Article.
More posts featuring Francisco J. Esteva.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023